Lepu Medical begins phase II trial for weight loss drug MWN105

Lepu Medical Technology announced that its subsidiary, Shanghai Minwei Biotechnology, has administered the first dose to a subject in the Phase II clinical trial for MWN105 injection. This innovative drug, a GLP-1/GIP/FGF21 receptor triple agonist, is being developed to treat overweight and obese individuals.

The Phase II multi-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of MWN105 injection in non-diabetic participants over 24 weeks. The primary endpoint is the percentage change in body weight from baseline after 24 weeks of dosing. MWN105 received approval for clinical trials in November 2024 from the National Medical Products Administration.

Pre-clinical results have shown MWN105's potential to significantly reduce weight, body fat, and liver weight, while also improving blood glucose levels and liver function in various animal models. The company emphasized that the project is in an early development stage, with inherent risks associated with clinical trials, regulatory approval, and market competition.